Prat-Quinzaños Jordi, Deniel-Rosanas Joan, Roura-Poch Pere, Casas-Capdevila Maria-Àngels, Farré-Guerrero Victor
Laboratory Medicine, Clinical Laboratory, Vic University Hospital, Vic, Barcelona, Spain.
Family and Community Medicine, Manlleu Primary Care Centre, Manlleu, Barcelona, Spain.
BMC Public Health. 2025 Jan 27;25(1):331. doi: 10.1186/s12889-025-21294-6.
Various studies confirm that the prevalence of dyslipidemia and other cardiovascular factors is high.
To evaluate the trend of the lipid profile (LP) in a cohort with severe hypercholesterolemia and its relationship with lipid-lowering treatment during the period 2009-2021.
Cross-sectional study carried out in the Osona county (Barcelona). Outpatients from the first period (2009-2011) who were aged between 25 and 65 years and had severe hypercholesterolemia were selected (n = 2,608). In a second period (2019-2021), these patients (n = 1,855) were followed up to evaluate the trend of LP and its relationship with lipid-lowering treatment. The Student's T-test (paired data) was used to identify differences between observations from the two periods.
Lipid-lowering treatment was prescribed to 61.9% of patients. The group of patients of the cohort improved the data of the mean results of the LP. Approximately 75% of cases were unable to establish their cholesterol and atherogenic fraction values. The prescription of lipid-lowering treatment in the cardiovascular disease group (CVD) was 80.9% vs 61.9% of the total cohort.
Three out of four cases failed to reduce the levels of LDL-C and non-HDL-C, recommended by the guidelines of scientific societies. Primary Care is the ideal framework to implement improvement strategies to control severe hypercholesterolemia, and it is therefore essential to strengthen it.
多项研究证实血脂异常和其他心血管因素的患病率很高。
评估2009 - 2021年期间重度高胆固醇血症队列中血脂谱（LP）的变化趋势及其与降脂治疗的关系。
在奥索纳县（巴塞罗那）开展横断面研究。选取第一阶段（2009 - 2011年）年龄在25至65岁之间且患有重度高胆固醇血症的门诊患者（n = 2608）。在第二阶段（2019 - 2021年），对这些患者（n = 1855）进行随访，以评估LP的变化趋势及其与降脂治疗的关系。采用学生t检验（配对数据）来确定两个阶段观察结果之间的差异。
61.9%的患者接受了降脂治疗。该队列患者组改善了LP平均结果的数据。约75%的病例无法确定其胆固醇和致动脉粥样硬化分数值。心血管疾病组（CVD）的降脂治疗处方率为80.9%，而整个队列的处方率为61.9%。
四分之三的病例未能降低科学协会指南推荐的低密度脂蛋白胆固醇（LDL-C）和非高密度脂蛋白胆固醇（non-HDL-C）水平。初级保健是实施控制重度高胆固醇血症改善策略的理想框架，因此加强初级保健至关重要。
